연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
525. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Han, S. W. Kim, T. Y. Lee, K. H. Hwang, P. G. Jeon, Y. K. Oh, D. Y. Lee, S. H. Kim, D. W. Im, S. A. Chung, D. H. Heo, D. S. Bang, Y. J.
Lung Cancer 2006; 54:201-207.
Link
524. 8-hydroxydeoxyguanosine suppresses NO production and COX-2 activity via Rac1/STATs signaling in LPS-induced brain microglia.
Kim HS, Ye SK, Cho IH, Jung JE, Kim DH, Choi S, Kim YS, Park CG, Kim TY, Lee JW, Chung MH.
Free Radic Biol Med. 2006 Nov 1;41(9):1392-403.
Link
523. Integrin signaling and cell spreading mediated by phorbol 12-myristate 13-acetate treatment.
Lee MS, Kim YB, Lee SY, Kim JG, Kim SH, Ye SK, Lee JW.
Journal of Cellular Biochemistry 2006,99;88-95
Link
522. Epigenetic regulation of Integrin-Linked Kinase expression depending on adhesion of gastric carcinoma cells. American Journal of Physiology-Cell Physiology.
Kim YB, Lee SY, Ye SK, Lee JW.
September20,2006.doi:10.1152/ajpcell.00169.2006
Link
521. Focal adhesion and actin organization by a cross-talk of TM4SF5with integrin α2 are regulated by serum treatment.
S-Y Lee, TY KIM, M-S Lee, Y-B Kim, E Chung, S KIM, and J W Lee.
Experimenttal Cell Research. 2006,312;2983-2999
Link
520. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Son MJ, Kim J-S, Kim MH, Song HS, Kim JT, Kim H, Shin T, Jeon HJ, Lee D-S, Park S-Y, Kim Y-J, Kim J-H, Nam D-H.
Int J Oncol 28:53-59, 2006
Link
519. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH.
Oncol Rep 16:33-39, 2006
Link
518. Age-dependent Expression of immune-privilege and proliferation-related molecules on the porcine Sertoli cells.
Lee H-M, Oh BC, Yang J-H, Cho J, Lee G, Lee D-S, Hwang WS, Lee JR.
Xenotransplantation 13:69-74, 2006
Link
517. Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
Moon, H. W. Shin, S. Kim, H. Y. Kim, Y. R. Cho, H. I. Yoon, S. S. Park, S. Kim, B. K. Chun, H. Kim, H. C. Park, C. J. Min, Y. H. Lee, D. S.
Leukemia 2006; 20:1408-1413.
Link
516. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
Lee, Y. K. Kim, Y. R. Min, H. C. Oh, B. R. Kim, T. Y. Kim, Y. S. Cho, H. I. Kim, H. C. Lee, Y. S. Lee, D. S.
Cancer Genet Cytogenet 2006; 166:65-73.
Link